Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 493-505

  Blanco, Almudena ^a   Álvarez, Susana ^b   Fresno, Manuel ^b   Muoz Fernández, Ma Ángeles ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b CSIC   (Spain)

Author keywords

Alzheimer's disease; astrocytes; COX 2 NF B

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E2;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTOMA CELL; CELL VIABILITY; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NEUROTOXICITY; PATHOGENICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 78650820931     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100309     Document Type: Article

References (58)

1. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399
2. ALesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440
3. Diaz-Nido J, Wandosell F, Avila J (2002) Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurode generative diseases. Peptides 23, 1323-1332.
4. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12, 1005-1015.
5. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and Annu Rev Pharmacol Toxicol 38
6. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69, 145-182.
7. Bazan NG, Colangelo V, Lukiw WJ (2002) Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat 68-69, 197-210.
8. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57, 295-303.
9. Qin W, Ho L, Pompl PN, Peng Y, Zhao Z, Xiang Z, Robakis NK, Shioi J, Suh J, Pasinetti GM (2003) Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem 278, 50970-50977.
10. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cy-clooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371-386.
11. Phillis JW, Horrocks LA, Farooqui AA (2006) Cyclooxyge-nases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 52, 201-243.
12. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Mar-nett LJ, Roberts LJ, 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53, 1495-1498.
13. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veer-huis R, Eikelenboom P (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 101, 2-8.
14. Pasinetti GM, Aisen PS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87, 319-324.
15. Xiang Z, Ho L, Yemul S, Zhao Z, Qing W, Pompl P, Kelley K, Dang A, Teplow D, Pasinetti GM (2002) Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. GeneExpr 10, 271-278.
16. Aisen PS (2002) Evaluation of selective COX-2 inhibitors for the treatment ofAlzheimer's disease. J Pain Symptom Manage 23, S35-S40.
17. Moore AH, O'Banion MK (2002) Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug DelivRev 54, 1627-1656.
18. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008) Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 14, 1419-1427.
19. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J, Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain 131, 651-664.
20. Weggen S, Rogers M, Eriksen J (2007) NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 28, 536-543.
21. Yamamoto K, Arakawa T, Ueda N, Yamamoto S (1995) Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 270, 31315-31320.
22. Mestre JR, Mackrell PJ, Rivadeneira DE, Stapleton PP, Tan-abe T, Daly JM (2001) Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-2 gene expression in endotoxin-treated macrophage/monocytic cells. J Biol Chem 276, 3977-3982.
23. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M (2000) An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275, 23627-23635.
24. Hernandez GL, Volpert OV, Iniguez MA, Lorenzo E, Martinez-Martinez S, Grau R, Fresno M, Redondo JM (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase J Exp Med 193, 607-620.
25. Subbaramaiah K, Telang N, Bansal MB, Weksler BB, Dan-nenberg AJ (1997) Cyclooxygenase-2 gene expression is up-regulated in transformed mammary epithelial cells. Ann N Y Acad Sci 833, 179-185.
26. Pasinetti GM (2002) From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 4, 435-445.
27. Zhang X, Luhrs KJ, Ryff KA, Malik WT, Driscoll MJ, Culver B (2009) Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS 1dE9 mice. Neuroscience 161, 53-58.
28. Yagami T, Ueda K, Asakura K, Sakaeda T, Kuroda T, Hata S, Kambayashi Y, Fujimoto M (2001) Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol 134, 673-681.
29. Bruno V, Battaglia G, Copani A, Cespedes VM, Galindo MF, Cena V, Sanchez-Prieto J, Gasparini F, Kuhn R, Flor PJ, Nicoletti F (2001) An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur J Neurosci 13, 14691478.
30. Ishige K, Chen Q, Sagara Y, Schubert D (2001) The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J Neurosci 21, 6069-6076.
31. Blanco A, Alvarez S, Fresno M, Munoz-Fernandez MA (2008) Extracellular HIV-Tat induces cyclooxygenase-2 in glial cells through activation of nuclear factor of activated T cells. J Immunol 180, 530-540.
32. Sales KJ, Grant V, Jabbour HN (2008) Prostaglandin E2 and F2alpha activate the FP receptor and up-regulate cyclooxygenase-2 expression via the cyclic AMP response element. Mol Cell Endocrinol 285, 51-61.
33. Li RC, Pouranfar F, Lee SK, Morris MW, Wang Y, Gozal D (2008) Neuroglobin protects PC12 cells against beta-amyloid-induced cell injury. Neurobiol Aging 29, 1815-1822.
34. Wang B, Wang XM (2009) Schisandrin B protects rat cortical neurons against Abeta1-42-induced neurotoxicity. Pharmazie 64, 450-454.
35. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C (2004) Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 55, 668-675.
36. Sasaki S, Kurosaki F, Haradahira T, Yamamoto F, Maeda J, Okauchi T, Suzuki K, Suhara T, Maeda M (2004) Synthesis of 11C-labelled bis(phenylalkyl)amines and their in vitro and in vivo binding properties in rodent and monkey brains. Biol PharmBull 27, 531-537.
37. Im JY, Kim D, Paik SG, Han PL (2006) Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. FreeRadic Biol Med 41, 960-972.
38. Kim JI, Jin JK, Choi EK, Spinner D, Rubenstein R, Carp RI, Kim YS (2007) Increased expression and localization of cyclooxygenase-2 in astrocytes of scrapie-infected mice. J Neuroimmunol 187, 74-82.
39. Zheng LT, Ock J, Kwon BM, Suk K (2008) Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglialactivation and neurotoxicity. Int Immunopharmacol 8, 484494.
40. Kim HT, Qiang W, Liu N, Scofield VL, Wong PK, Stoica G (2005) Up-regulation of astrocyte cyclooxygenase-2, CCAAT/enhancer-binding protein-homology protein, glucose-related protein 78, eukaryotic initiation factor 2 alpha, and c-Jun N-terminal kinase by a neurovirulent murine retrovirus. JNeurovirol 11, 166-179.
41. Chakraborty S, Kaushik DK, Gupta M, Basu A (2010) In-flammasome signaling at the heart of central nervous system pathology. J Neurosci Res 88, 1615-1631
42. Li P, Lu J, Kaur C, Sivakumar V, Tan KL, Ling EA (2009) Expression of cyclooxygenase-1/-2, microsomal prostaglandin-E synthase-1 and E-prostanoid receptor 2 and regulation of inflammatory mediators by PGE(2) in the amoeboid microglia in hypoxic postnatal rats and murine BV-2 cells. Neuroscience 164, 948-962.
43. Alvarez S, Blanco A, Fresno M, Munoz-Fernandez MA (2010) Nuclear factor-kappaB activation regulates cyclooxygenase-2 induction in human astrocytes in response to CXCL12: role in neuronal toxicity. JNeurochem 113, 72-783.
44. Pan XD, Chen XC, Zhu YG, Chen LM, Zhang J, Huang TW, Ye QY, Huang HP (2009) Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 57, 1227-1238.
45. Franciosi S, Choi HB, Kim SU, McLarnon JG (2005) IL-8 enhancement of amyloid-beta (Abeta 1-42)-induced expression and production of pro-inflammatory cytokines and COX-2 in cultured human microglia. J Neuroimmunol 159, 66-74.
46. Alvarez S, Serramia MJ, Fresno M, Munoz-Fernandez M (2005) Human immunodeficiency virus type 1 envelope glyco-protein 120 induces cyclooxygenase-2 expression in neurob-lastoma cells through a nuclear factor-kappaB and activating protein-1 mediated mechanism. J Neurochem 94, 850-861.
47. Alvarez S, Blanco A, Kern F, Fresno M, Munoz-Fernandez MA (2008) HIV-2 induces NF-kappaB activation and cyclooxygenase-2 expression in human astroglial cells. Virology 380, 144-151.
48. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ, 2nd (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44, 410-413.
49. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: structures, properties, and functions. Physiol Rev 79, 1193-1226.
50. Carrasco E, Casper D, Werner P (2007) PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. J Neurosci Res 85, 3109-3117.
51. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K (2008) Misoprostol, an antiulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett 438, 210-215.
52. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12, 225-229.
53. Echeverria V, Clerman A, Dore S (2005) Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against ox-idative stress and cell death following beta-amyloid exposure. Eur J Neurosci 22, 2199-2206.
54. Jang JH, Surh YJ (2005) Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic Biol Med 38, 1604-1613.
55. Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG (2004) Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia 48, 85-90.
56. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A (2009) Astroglia in dementia and Alzheimer's disease. Cell Death Differ 16, 378-385.
57. Parachikova A, Cotman CW (2007) Reduced CX-CL12/CXCR4 results in impaired learning and is downregu-lated in a mouse model of Alzheimer disease. Neurobiol Dis 28, 143-153.
58. Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677.